Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.565 USD | +0.38% | +0.38% | -36.32% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.32% | 188M | |
+9.22% | 220B | |
+15.91% | 198B | |
+23.54% | 148B | |
+31.26% | 112B | |
+4.68% | 66.17B | |
+14.90% | 52.47B | |
+4.85% | 50.77B | |
-3.73% | 38.97B | |
-0.75% | 35.13B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Leerink Partners Initiates NeuroPace at Outperform Rating With $22 Price Target